Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Wednesday 11 November 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Market Access

Financial global growth trajectory

Biotech's next growth cycle: Renewed confidence comes with c...

Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.

Oncology

Cancer cells

The future of oncology is adaptive: What ESMO 2026 revealed ...

Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.

Market Access

Solution Spotlight: Acumetis Model Builder

Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Patients

Claire Gillis, CEO - VML Health

Healthcare wants patients at the centre. So, why are they st...

Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.

Digital

Synthetic data idea, motherboard and lights

The growing use of synthetic data in modern pharma

The issue isn't whether synthetic data is useful. It is what question we are asking it to answer.

Articles

Interview with Kevin Hrusovsky part 3: the role of next generation sequencing in personalized medicine

Interview with Kevin Hrusovsky part 3: the role of next gene...

Kevin Hrusovsky of PerkinElmer Inc. discusses the role of next generation sequencing in personalized medicine in the concluding part of his interview. Previously in this three-part interview Kevin shared with us the most recent exciting advances in the understanding of molecular interactions...

Articles

The evolution of personalised healthcare within oncology

The evolution of personalised healthcare within oncology

Chris Teale discusses personalised medicine within the oncology field, looking at the way pharma now thinks about healthcare and some of the current barriers in companion diagnostics. The evolution of personalised healthcare has changed the diagnosis and prognosis of cancer patients. But in order to...

Articles

Interview with Kevin Hrusovsky part 2: next generation sequencing

Interview with Kevin Hrusovsky part 2: next generation seque...

In the second part of this three-part interview, Kevin Hrusovsky discusses next generation sequencing. In part one of this three-part interview, Kevin Hrusovsky highlighted some exciting recent advances in the understanding of molecular...

Load more results

Sales & Marketing

Sales & Marketing

Solution Spotlight: BrandPRO Biopharma

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Digital

Synthetic data idea, motherboard and lights

The growing use of synthetic data in modern pharma

The issue isn't whether synthetic data is useful. It is what question we are asking it to answer.

Digital

AI graphic concept

AI is exposing a new digital maturity divide in pharma busin...

As AI adoption increases, it is exposing just how prepared organisations really are to operate in a digitally connected environment.

Market Access

Market Access

Financial global growth trajectory

Biotech's next growth cycle: Renewed confidence comes with c...

Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.

Market Access

Solution Spotlight: Acumetis Model Builder

Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Editor's Picks

Boehringer forges $7bn alliance with China's SBP Group News

Lilly partners with Hims & Hers on obesity drug sales

UK women's health firm Theramex sold for around £2.2bn

What do midterms mean for Trump's pharma and health agenda?

NICE backs Keytruda/Padcev combo for bladder cancer

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Cancer cells

The future of oncology is adaptive: What ESMO 2026 revealed ...

Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.

Oncology

Digital concept of a lung cancer vaccine

Lung cancer vaccine renews synthetic DNA discussions

pharmaphorum spoke with Dr Amy Walker, CEO of 4basebio, about personalised cancer vaccines and synthetic DNA.

Oncology

Woman with breast cancer and female HCP

How precision medicine treats an overlooked clinical variabl...

In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.

Patients

Patients

Claire Gillis, CEO - VML Health

Healthcare wants patients at the centre. So, why are they st...

Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.

Deep Dive

Why are so few sickle cell disease patients using a widely available treatment?

Why are so few sickle cell disease patients using a widely a...

Patients

TMS being given to female patient by female HCP.

TMS works. Why do fewer than 1% of eligible patients get it?

A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.

R&D

R&D

Aedes aegypti mosquito

Europe’s growing vector-borne disease threat: Are we keeping...

In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.

R&D

Digital illustration of the kidneys

Kidney care raises its ambitions at ASN Kidney Week 2026

Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.

R&D

Challenging the clinical trial plan

Why the best CROs challenge the trial plan and keep challeng...

Too often, oncology trials fail for reasons that could have been anticipated and addressed.

Editor's Picks

Boehringer forges $7bn alliance with China's SBP Group News

Lilly partners with Hims & Hers on obesity drug sales

UK women's health firm Theramex sold for around £2.2bn

What do midterms mean for Trump's pharma and health agenda?

NICE backs Keytruda/Padcev combo for bladder cancer

News

Third Rock in $2bn drug-hunting pact with China's Funnel

New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Securing your ROI: Turning post-acquisition integration into operational and strategic value

Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company